A number of firms have modified their ratings and price targets on shares of Thermo Fisher Scientific (NYSE: TMO) recently:
- 10/23/2026 – Thermo Fisher Scientific had its price target raised by Citigroup from $685.00 to $800.00. They now have a “buy” rating on the stock.
- 10/23/2026 – Thermo Fisher Scientific was downgraded by DZ Bank from “strong-buy” to “hold”.
- 10/22/2026 – Thermo Fisher Scientific had its “buy” rating reaffirmed by UBS Group. They now have a $800.00 price target on the stock.
- 10/22/2026 – Thermo Fisher Scientific had its price target raised by Royal Bank Of Canada from $580.00 to $730.00. They now have a “sector perform” rating on the stock.
- 10/22/2026 – Thermo Fisher Scientific had its price target raised by Barclays from $750.00 to $775.00. They now have an “overweight” rating on the stock.
- 10/22/2026 – Thermo Fisher Scientific had its price target raised by TD Cowen from $760.00 to $810.00. They now have a “buy” rating on the stock.
- 10/22/2026 – Thermo Fisher Scientific had its price target raised by Stifel Nicolaus from $650.00 to $775.00. They now have a “buy” rating on the stock.
- 10/22/2026 – Thermo Fisher Scientific had its price target raised by Robert W. Baird from $723.00 to $756.00. They now have an “outperform” rating on the stock.
- 10/15/2026 – Thermo Fisher Scientific was given a new $740.00 price target by Royal Bank Of Canada.
- 10/15/2026 – Thermo Fisher Scientific is now covered by Guggenheim. They set a “buy” rating on the stock.
- 10/15/2026 – Thermo Fisher Scientific had its “buy” rating reaffirmed by Guggenheim. They now have a $740.00 price target on the stock.
- 10/13/2026 – Thermo Fisher Scientific had its price target raised by TD Cowen from $675.00 to $760.00. They now have a “buy” rating on the stock.
- 10/12/2026 – Thermo Fisher Scientific had its price target raised by Morgan Stanley from $650.00 to $730.00. They now have an “overweight” rating on the stock.
- 10/8/2026 – Thermo Fisher Scientific was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
- 10/7/2026 – Thermo Fisher Scientific had its price target raised by Barclays from $650.00 to $750.00. They now have an “overweight” rating on the stock.
- 10/3/2026 – Thermo Fisher Scientific was upgraded by Wall Street Zen from “hold” to “buy”.
- 9/25/2026 – Thermo Fisher Scientific had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $720.00 price target on the stock.
- 9/12/2026 – Thermo Fisher Scientific was downgraded by Wall Street Zen from “buy” to “hold”.
- 9/9/2026 – Thermo Fisher Scientific is now covered by Piper Sandler. They set an “overweight” rating on the stock.
- 9/9/2026 – Thermo Fisher Scientific is now covered by Scotiabank. They set an “outperform” rating on the stock.
- 9/9/2026 – Thermo Fisher Scientific was downgraded by BMO Capital Markets to “market perform”.
- 9/9/2026 – Thermo Fisher Scientific was downgraded by Wells Fargo & Company from “overweight” to “underweight”.
- 9/9/2026 – Thermo Fisher Scientific was downgraded by Citigroup from “buy” to “underperform”.
- 9/9/2026 – Thermo Fisher Scientific was downgraded by Deutsche Bank Aktiengesellschaft from “buy” to “hold”.
- 9/8/2026 – Thermo Fisher Scientific was upgraded by UBS Group from “neutral” to “buy”. They now have a $730.00 price target on the stock, up from $540.00.
- 9/3/2026 – Thermo Fisher Scientific is now covered by CLSA. They set an “outperform” rating and a C$748.00 price target on the stock.
- 9/3/2026 – Thermo Fisher Scientific is now covered by CLSA. They set a “moderate buy” rating and a C$748.00 price target on the stock.
- 9/1/2026 – Thermo Fisher Scientific was upgraded by HSBC from “hold” to “strong-buy”.
Insiders Place Their Bets
In related news, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 275 shares of the firm’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,707,171.25. This trade represents a 0.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 73,368 shares of company stock valued at $43,896,820. 0.33% of the stock is owned by company insiders.
Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.
Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.
Read More
- Five stocks we like better than Thermo Fisher Scientific
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.
